Cartesian Therapeutics

Cartesian Therapeutics P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Cartesian Therapeutics (RNAC) as of Oct 19, 2026 is -2.29. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -7.16 — a change of -67.98% (higher).

P/CF

-2.29

YoY

-67.98%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Cartesian Therapeutics is 2025 -2.29 . P/CF (Price-to-Cash-Flow Ratio) of Cartesian Therapeutics was 2024 -7.16 . It decreases by -67.98% higher compared to the previous year.

The Cartesian Therapeutics P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-2.87 USD
Jan 1, 2019
-3.30 USD
Jan 1, 2020
4.86 USD
Jan 1, 2021
-2.81 USD
Jan 1, 2022
-5.36 USD
Jan 1, 2023
-3.31 USD
Jan 1, 2024
-7.16 USD
Jan 1, 2025
-2.29 USD
The Cartesian Therapeutics P/CF history
YEARP/CFYoY
-2.29-67.98%
-7.16+116.11%
-3.31-38.17%
-5.36+90.90%
-2.81-157.77%
4.86-247.46%
-3.30+15.02%
-2.87-12.04%
-3.26-62.17%
-8.61+14.12%
-7.55-43.52%
-13.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cartesian Therapeutics Stock analysis

What does Cartesian Therapeutics do? Cartesian Therapeutics Inc, trading under the ticker RNAC, is a biotechnology company based in Watertown, United States. The company has 75 employees and went public via an IPO on June 22, 2016. Cartesian Therapeutics operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://selectabio.com/. Cartesian Therapeutics focuses on developing therapeutic solutions, though specific product names or clinical stage details are not provided in the available information. The company's headquarters are located in Watertown, and it is engaged in research and development activities typical of a biopharmaceutical firm. Cartesian Therapeutics is identified by its ISIN number US8162123025. The company's activities are centered around advancing biotechnology for healthcare applications, with a focus on innovative therapeutic approaches. The company's operational scope and specific research areas are not detailed beyond the general biotechnology sector focus. Cartesian Therapeutics is a clinical-stage biopharmaceutical company, though the exact stage of clinical development for any specific therapy is not specified in the provided data. The company's website serves as a primary source of information for further details on its operations and developments. Cartesian Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cartesian Therapeutics stock

P/CF (Price-to-Cash-Flow Ratio) of Cartesian Therapeutics is -2.29 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Cartesian Therapeutics changed from -7.16 to -2.29, representing a -67.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Cartesian Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Cartesian Therapeutics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Cartesian Therapeutics